Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway

Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway

Hui Chen,1–4 Qiang Zhang,1–4 Yu Zhang,1–4 Bin Jia,1–4 Bin Zhang,1–4 Changli Wang1–4 1Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People&rsq...

Full description

Bibliographic Details
Main Authors: Chen H, Zhang Q, Zhang Y, Jia B, Zhang B, Wang C
Format: Article
Language:English
Published: Dove Medical Press 2018-11-01
Series:OncoTargets and Therapy
Subjects:
afatinib
ceritinib
NRG1
lung cancer
ALK/ROS1
Online Access:https://www.dovepress.com/afatinib-reverses-ceritinib-resistance-cr-in-alkros1-positive-non-smal-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/afatinib-reverses-ceritinib-resistance-cr-in-alkros1-positive-non-smal-peer-reviewed-article-OTT

Similar Items